N Engl J Med

AHA 2024: Intensive BP control beneficial in patients with T2DM

November 19, 2024

Intensive blood pressure control significantly reduces the risk of major CV events in patients with T2DM, according to findings shared at the American Heart Association’s Scientific Sessions.

The study

The BPROAD trial enrolled 12,821 adults ages ≥50 years with T2DM, elevated systolic BP, and an increased risk of heart disease across 145 sites in China. Participants were randomized to either intensive antihypertensive therapy (systolic BP target: <120 mm Hg) or standard therapy (systolic BP target <140 mm Hg). Primary outcome was a composite of nonfatal stroke, nonfatal MI, treatment or hospitalization for heart failure, or death from CV causes.

Key findings

At one year follow-up, mean systolic BP was 121.6 mm Hg (median, 118.3 mm Hg) in the intensive-treatment group and 133.2 mm Hg (median, 135.0 mm Hg) in the standard-treatment group. Over the 4-year follow-up period, the intensive-treatment group had a 21% lower relative risk of major CV events, with 1.65 events per 100 person-years experiencing events vs. 2.09 events per 100 person-years in the standard-treatment group. Both groups had similar rates of serious adverse events, though symptomatic hypotension and hyperkalemia were more frequent in the intensive group.

Source:

Bi Y; et al BPROAD Research Group. (2024, November 16). N Engl J Med. Intensive Blood-Pressure Control in Patients with Type 2 Diabetes. https://pubmed.ncbi.nlm.nih.gov/39555827/